Structure Therapeutics Inc. (GPCR)
| Market Cap | 1.70B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -89.62M |
| Shares Out | 46.60M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,520 |
| Open | 36.09 |
| Previous Close | 36.09 |
| Day's Range | 35.75 - 37.19 |
| 52-Week Range | 21.79 - 75.02 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 82.20 (+125.64%) |
| Earnings Date | May 14, 2024 |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular di... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for GPCR stock is "Strong Buy." The 12-month stock price forecast is $82.2, which is an increase of 125.64% from the latest price.
News
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Wegovy and Zepbound Are King. Who's Coming for Their Crowns.
Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me...
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space
Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
Structure Therapeutics reports promising results for weight-loss pill
Structure Therapeutics Inc (NASDAQ: GPCR) says its experimental weight-loss pill showed promising results in a mid-stage trial. Its shares are still down more than 40% at writing.
New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.
Biotech Structure saw shares dive after the firm disclosed disappointing data for an experimental obesity pill.
Structure's diabetes pill misses weight-loss expectations in mid-stage trial
Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results from a similar treatment from rival Eli Lilly, sending the biotech compa...
Structure Therapeutics stock plunges on new GLP-1 drug data
Structure Therapeutics Inc. American depositary receipts GPCR, +0.97% dropped 40% premarket on Monday after the company released new data from a study of GSBR-1290, its investigational diabetes and ob...
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% st...
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and tole...
Final Trades: Rivian, Pfizer, Treasury Bonds and more
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy.
Structure Therapeutics surges on promising early stage obesity drug data
Shares of Structure Therapeutics soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study.
Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement
Structure Therapeutics Inc.'s American depositary receipts GPCR, +4.96% jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss...
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of f...
Structure Therapeutics Appoints Ted W. Love, M.D.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...
Structure Therapeutics to Present at Jefferies Healthcare Conference
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeu...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 Posters include data across biomarker, translation an...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half 2...